^
Association details:
| Biomarker: | BCL2 expression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Excerpt:
...- For the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors must have evidence of BCL-2 expression (except participants with TCF3-HLF ALL)....
Trial ID:
Source:
Title:
Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression
Published date:
11/06/2019
Excerpt:
...analyses demonstrate that VEN + HMA or LDAC has efficacy across multiple molecular markers in AML. This activity is rapid and durable, and is observed across different levels of BCL2 expression in AML blasts.
Secondary therapy:
cytarabine; Hypomethylating agent
DOI:
https://doi.org/10.1182/blood-2019-128373
Source:
Title:
Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML
Published date:
11/01/2018
Excerpt:
To identify biomarkers associated with venetoclax sensitivity, we developed an integrative Bayesian machine learning method that jointly modeled both data sets, revealing several candidate biomarkers positively (BCL2 and FLT3) or negatively (CD14, MAFB, and LRP1) correlated with venetoclax response.
DOI:
10.1182/blood-2018-99-111916
Source:
Title:
Bcl-2 (B-cell lymphoma 2) expression level as potential biomarker for venetoclax sensitivity in acute myeloid leukemia [AML] without druggable genetic aberrations: A case report
Published date:
09/03/2020
Excerpt:
We confirm excellent sensitivity of Bcl-2 expressing AML blasts to 2nd line Venclyxto® after failure of 1st line HMA.
